Skip survey header
Low Vision Mode

Registration for COVID-19 Monoclonal Antibody Allocation

Effective immediately, the process to obtain therapeutics has moved to direct ordering instead of an allocation process. Texas DSHS has done its last allocation to facilities in the state and you can now place direct orders for your facility with AmerisourceBergen (ABC). Treatment sites should review the direct ordering process guide and place orders directly at this site. The products remain free of charge to requesting sites. Sites that have not received a shipment from ABC will be required to: • select their type of facility • attest that the therapies will be used according to their respective EUAs • provide either a Texas pharmacy license number or a letter of authorization, signed by a physician or nurse practitioner. The federal government is requiring enrollment in their Teletracking reporting system for facilities that are not reporting via another system, such as CDC's National Healthcare Safety Network (NHSN) or HHS Protect. Weekly reporting to Teletracking is required on Wednesdays and consists of two numbers: 1) weekly usage and 2) on-hand inventory. At this time, there are no changes to the state reporting requirements. You can find addition information about therapeutics, including the EUAs and factsheets at DSHS COVID-19 Therapeutics. For facilities and healthcare providers interested in setting up infusions for high-risk patients with COVID-19, this is a valuable resource: Project ECHO Outpatient Therapeutics Mini-Series. ASPR and HHS also has free digital content that your facility can use on social media platforms to help educate providers and patients plus is a resource for your patients. Should you have any questions or concerns regarding the direct order process for COVID-19 monoclonal antibodies, you may contact HHS/ASPR at or ABC at Other questions regarding monoclonal antibodies may be sent to DSHS at